1. 昆明医科大学第三附属医院,云南省肿瘤医院,北京大学肿瘤医院云南医院肿瘤防治办公室,昆明,650118
2. 昆明医科大学第三附属医院,云南省肿瘤医院,北京大学肿瘤医院云南医院感染管理科,昆明,650118
3. 昆明医科大学第三附属医院,云南省肿瘤医院,北京大学肿瘤医院云南医院门诊部,昆明,650118
4. 昆明医科大学第三附属医院,云南省肿瘤医院,北京大学肿瘤医院云南医院医务部,昆明,650118
蔡瑞琪,女,硕士在读,主要从事肿瘤流行病学研究,ORCID: 0009-0004-6424-4474
杨志坚,男,硕士在读,主要从事恶性肿瘤卫生经济评价工作,ORCID: 0009-0001-6783-1613
赵敏,男,博士,副主任医师,主要从事肿瘤流行病学研究,E-mail: 573532996@qq.com,ORCID: 0000-0003-1347-5788
纸质出版:2026
移动端阅览
蔡瑞琪, 杨志坚, 杨颜颜, 马国玉, 庞钰莹, 张梦娇, 罗镭, 李四乐, 赵敏. 云南省4892例结直肠癌患者生存的影响因素分析[J]. 肿瘤防治研究, 2026, 53(4): 274-280.
CAI Ruiqi, YANG Zhijian, YANG Yanyan, et al. Factors Affecting Survival of 4892 Patients with Colorectal Cancer in Yunnan Province[J]. 2026, 53(4): 274-280.
蔡瑞琪, 杨志坚, 杨颜颜, 马国玉, 庞钰莹, 张梦娇, 罗镭, 李四乐, 赵敏. 云南省4892例结直肠癌患者生存的影响因素分析[J]. 肿瘤防治研究, 2026, 53(4): 274-280. DOI: 10.3971/j.issn.1000-8578.2026.25.0751.
CAI Ruiqi, YANG Zhijian, YANG Yanyan, et al. Factors Affecting Survival of 4892 Patients with Colorectal Cancer in Yunnan Province[J]. 2026, 53(4): 274-280. DOI: 10.3971/j.issn.1000-8578.2026.25.0751.
目的
分析云南省结直肠癌患者的生存状况及其影响因素。
方法
回顾性收集
4892
例结直肠癌患者的临床资料。通过随访获取生存数据,采用Kaplan-Meier法计算总生存率(OS),Log-rank检验进行单因素分析,Cox比例风险回归模型进行多因素分析。
结果
全组患者的1、3、5、10年OS率分别为91.90%、74.40%、64.40%和28.70%。单因素分析结果显示,年龄、民族、地区、分化程度、TNM分期、临床分期、转移状态、组织学类型及治疗方式(化疗、放疗、手术)与患者预后相关(均
P
0.05)。多因素分析结果显示,年龄(
HR
=1.250)、地区(
HR
=1.262)、分化程度(
HR
=0.761)、临床分期(
HR
=3.128)及治疗方式(化疗:
HR
=0.644、放疗:
HR
=1.605、手术:
HR
=0.384)是影响结直肠癌患者生存预后的独立因素(均
P
0.001)。
结论
年龄、地区、临床分期和治疗方式是云南省结直肠癌患者生存的独立影响因素。临床实践中应结合这些因素制订个体化的防治策略,以期改善患者预后。
Objective
To analyze survival outcomes and influencing factors among patients with colorectal cancer in Yunnan Province.
Methods
Clinical data were retrospectively collected from 4 892 patients with colorectal cancer. Survival data were obtained through follow-
up. Overall survival (OS) was calculated by using the Kaplan-Meier method. Univariate analysis was performed by applying the log-rank test. Meanwhile
multivariate analysis employed the Cox proportional hazards regression model.
Results
The 1-
3-
5-
and 10-year OS rates for the entire cohort were 91.90%
74.40%
64.40%
and 28.70%
respectively. Univariate analysis revealed that age
ethnicity
region
differentiation grade
TNM stage
clinical stage
metastatic status
histological type
and treatment modality (chemotherapy
radiotherapy
and surgery) were associated with patient prognosis (all
P
0.05). Multivariate analysis identified age (
HR
=1.250)
region (
HR
=1.262)
differentiation grade (
HR
=0.761)
clinical stage (
HR
=3.128)
and treatment modality (chemotherapy
HR
=0.644; radiotherapy
HR
=1.605; surgery
HR
=0.384) as independent factors affecting survival prognosis in patients with colorectal cancer (all
P
0.001).
Conclusion
Age
region
clinical stage
and treatment modality are independent factors influencing survival among patients with colorectal cancer in Yunnan Province. In clinical practice
these factors should be integrated to develop individualized prevention and treatment strategies
thereby improving patient outcomes.
Klimeck L, Heisser T, Hoffmeister M, et al . Colorectal cancer: A health and economic problem[J ] . Best Pract Clin Gastroenterol, 2023, 66: 101839.
Han B, Zheng R, Zeng H, et al . Cancer incidence and mortality in China, 2022[J ] . J Natl Cancer Cent, 2024, 4(1): 47-53.
Chen MS, Chen Y, Shi QP, et al. Analysis of the current status of cancer incidence and mortality in Yunnan province in 2020[J]. Shi Yong Zhong Liu Xue Za Zhi, 2024, 38(5): 283-288.
Thanikachalam K, Khan G. Colorectal Cancer and Nutrition[J]. Nutrients, 2019, 11(1): 164.
Kim BJ, Hanna MH. Colorectal cancer in young adults[J]. J Surg Oncol, 2023, 127(8): 1247-1251.
Shen Y, Cai H, Zhou D, et al . Differences in th e epidemiology and survival of patients with colorectal cancer between China and the United States: a large cross-sectional study[J ] . Updates Surg, 2025, 77(1): 119-132.
Allemani C, Matsuda T, Di Carlo V, et al . Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37, 513, 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J ] . Lancet, 2018, 391(10125): 1023-1075.
Matsuda T, Fujimoto A, Igarashi Y. Colorectal Cancer: Epidemiology, Risk Factors, and Public Health Strategies[J]. Digestion, 2025, 106(2): 91-99.
Li YF, Liu X, Li SM, et al. Independent prognostic factors and prediction models construction of patients with stage ⅡA colorectal cancer[J]. Fen Zi Ying Xiang Xue Za Zhi, 2024, 47(7): 713-720.
Yue T, Chen S, Zhu J, et al . The aging-related risk signature in colorectal cancer[J ] . Aging (Albany NY), 2021, 13(5): 7330-7349.
Fu MS , Pan SX, Cai XQ, et al . Urban vs. rural: colorectal cancer survival and prognostic disparities from 2000 to 2019[J ] . Front Public Health, 2024, 12: 1319977.
Shivji S, Conner JR, Barresi V, et al . Poorly differentiated clusters in colorectal cancer: a current review and implications for future practice[J ] . Histopathology, 2020, 77(3): 351-368.
Qi Z, Zhibo Z, Jing Z, et al . Prediction model of poorly differentiated colorectal cancer (CRC) based on gut bacteria[J ] . BMC Microbiol, 2022, 22(1): 312.
Amin MB, Greene FL, Edge SB, et al . The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging[J ] . CA Cancer J Clin, 2017, 67(2): 93-99.
Lea D, Håland S, Hagland HR, et al . Accuracy of TNM staging in colorectal cancer: a review of current culprits, the modern role of morphology and stepping-stones for improvements in the molecular era[J ] . Scand J Gastroenterol, 2014, 49(10): 1153-1163.
Han Z, Yang H, Qiao Q, et al . The survival prediction of advanced colorectal cancer received neoadjuvant therapy—a study of SEER database[J ] . World J Surgical Oncol, 2024, 22(1): 175.
Baxter NN, Kennedy EB, Bergsland E, et al . Adjuvant Therapy for Stage Ⅱ Colon Cancer: ASCO Guideline Update[J ] . J Clin Oncol, 2022, 40(8): 892-910.
Tang Z, Zhou G, Xu Y, et al . Survival analysis and prediction of early-onset colorectal cancer patients post-chemotherapy: an analysis based on the SEER database[J ] . Int J Colorectal Dis, 2025, 40(1): 74.
Gulack BC, Nussbaum DP, Keenan JE, et al . Surgical Resection of the Primary Tumor in Stage Ⅳ Colorectal Cancer without Metastasectomy is Associated with Improved Overall Survival Compared to Chemotherapy/Radiation Therapy Alone[J ] . Dis Colon Rectum, 2016, 59(4): 299-305.
Agyemang-Yebosh F, Yorke J, Obirikorang C, et al . Colorectal cancer survival rates in Ghana: A retrospective hospital-based study[J ] . PLoS One, 2018, 13(12): e0209307.
Klement RJ, Abbasi-Senger N, Adebahr S, et al . The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases[J ] . BMC Cancer, 2019, 19(1): 173.
Aguiar Junior S, Oliveira MM, Silva DRME, et al . Survival of patients with colorectal cancer in a cancer center[J ] . Arq Gastroenterol, 2020, 57(2): 172-177.
Zhou CM, Guo TA, Mo M, et al. Survival report of 13.7 thousand surgical colorectal cancer patients from a large single hospital-based cancer registry[J]. Zhongguo Ai Zheng Za Zhi, 2020, 30(4): 246-253.
Li Y, Zhang J, Zhu AP, et al. Incidence Trends and Survival of Colorectal Cancer in Jiangyin City of Jiangsu Province from 2013 to 2018[J]. Zhongguo Zhong Liu, 2022, 31(11): 898-902.
Hu BB, Fu KB, Shao Z. Morbidity, mortality and survival of colorectal cancer in Yuyao, Zhejiang, 2015-2021[J]. Ji Bing Jian Ce, 2022, 37(9): 1230-1235.
Lin YL, Chen YL, Guo ZN, et al. Analysis of Epidemiological Characteristics and Survival of Cancers in Xiamen City of Fujian Province in 2020[J]. Zhongguo Zhong Liu, 2024, 33(11): 901-907.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621